isolates from infected individuals by determining the typespecific RT activity reduction owing to those antibodies in a non-RI RTA. We demonstrated and report here the utility of this non-RI RT-typing assay for differentiating HIV-1 from HIV-2.
MATERUILS AND METHODS
DNA polymerases and viruses. Two purified polymerases, Rous-associated virus type 2 (RAV-2) RT and DNA polymerase I (Klenow fragment) were purchased from TakaraShuzo, Co., Ltd., and one recombinant HIV-1 (rHIV-1) RT was purchased from Eiken Chemicals (29) . HIV-1 strains (LAV-lBRU and GH-3 [13] ) and HIV-2 strains (GH-1 [10] ; [12] ; GH-4, GH-5, and GH-6 [13] ; and LAV-2ROD) were cultured in the Molt-4 cell line. Each virus culture supernatant was mixed with a virus solubilizing buffer (27) , and the lysates were stored at 4°C. Viruses isolated from 18 HIV-1-seropositive patients with hemophilia and 3 HIV-2-seropositive Ghanaian individuals were obtained by cocultivation of peripheral blood mononuclear cells with normal donor cells (23) . Virus was detected in culture supernatants by a non-RI RTA (34) and an HIV-1 p24 antigen-capture enzyme-linked immunosorbent assay (ELISA) (21) . Additional zidovudine (AZT)-resistant mutants (mutants A012D and A018C [17, 18] ) and human T-cell leukemia virus type III strain B-R (HTLV-IIIB R) were examined.
RTI antibody. Sera from 23 asymptomatic HIV-1-seropositive patients with hemophilia (hRTI-1) and four rabbits immunized with rHIV-1 RT (rRTI-1) served as RTI antibody to (34) . Therefore, the enzyme preparations used for testing were serially diluted with NaCl-free virus-solubilizing buffer, which gave activity of between 0.500 and 1.200 absorbance units.
(i) RTI antibody assay. Twenty-five microliters of antibody preparation was mixed at 4°C for 60 min with 25 ,ul of polymerase or viral lysate (1, 30) . The RT activity of the mixture was assayed at 37°C for 18 to 24 h, and the percent residual RT activity was calculated as follows: (RT activity with RTI)/(RT activity with phosphate-buffered saline) x 100. The percentage of residual RT activity was rounded down, and a value of less than 25% was defined as positive inhibition according to the final results of the study.
(ii) RT-typing assay. Twenty-five microliters of each HIV coculture supernatant from 18 HIV-1-seropositive individuals and 3 HIV-2-seropositive individuals was mixed with 25 ,ul of antibodies (rRTI-1 and RTI-2) whose type specificities had been confirmed by the RTI antibody assay. The subsequent procedures were the same as those for the RTI antibody assay described above.
RESULTS
Four rabbit antiserum samples raised against recombinant HIV-1 RT (rRTI-1) and one antiserum sample against disrupted GH-1 (RTI-2) were examined for their reactivities to HIV-1 and HIV-2 proteins by using Western blot (immunoblot) kits (Fig. 1A and B) . All four rRTI-1 antiserum samples strongly reacted with HIV-1 RT bands, with one antiserum sample weakly cross-reacting with the HIV-1 gag protein (p25) but not with HIV-2 RT (Fig. 1A, lane 2) . RTI-2 reacted with most HIV-2 proteins and showed significant cross-reactivity with HIV-1 gag proteins (p55, p40, p25, and p18) but not with HIV-1 RT bands (Fig. 1A and B, lane 7) . All serum samples from 23 HIV-1-infected individuals (hRTI-1) showed strong binding to the protein bands on HIV-1 Western blot strips, and some serum samples recognized HIV-2 RT and gag proteins (p68 and p26). Results for a representative cross-reacting human serum sample are shown in Fig. 1B , lane 6. These antisera were tested at different concentrations for their RT-inhibiting activities for HIV-1 ( Fig. 2A ) and HIV-2 (Fig. 2B) . Antisera rRTI-1 and RTI-2 specifically inhibited the corresponding RTs in relation to their concentrations. In contrast, control sera from normal humans and rabbits failed to inhibit either HIV-1 or HIV-2 RT. We obtained residual RT activity of more than 100% with some samples in the RTtyping and the RTI antibody assays. This phenomenon, which has also been reported elsewhere (9, 11, 19, 28, 37) , may be caused by the presence of some other components in serum or enhancement by cross-reacting antibodies.
To further examine the specificities of RTI-1 and RTI-2, they were tested with two HIV-1 strains, one rHIV-1 RT, and six HIV-2 strains. Polymerases from RAV-2 and Escherichia coli served as control enzymes. The four rRTI-1 samples specifically inhibited all of the three different HIV-1 RTs, but not HIV-2 or RAV-2 RT (Table 1) . They also did not inhibit E. coli DNA polymerase I when assayed on a DNA-specific poly(dA) oligo(dT) template primer. On the other hand, RTI-2 antisera specifically inhibited RTs from all six different HIV-2 strains but none of the other enzymes (Table 2) . Two control serum samples did not inhibit the enzymes assayed. Sera from 23 HIV-1-seropositive individuals were tested for their inhibiting activities against five RTs ( Table 3 ). All of these serum samples specifically blocked the RTs of two HIV-1 strains (LAV-1BRU and GH-3) but not those of two HIV-2 strains (LAV-2ROD and GH-1) or RAV-2. We also tested these 23 serum samples for their type-specific inhibition of RTs of other HIV-1 and HIV-2 strains, and similar type specificities were observed (data not shown).
Using these type-specific RTI antibodies, we then typed clinical isolates from 18 HIV-1-seropositive individuals (Table   TABLE 1 
4) and AZT-resistant mutants.
RTs from all 18 clinical HIV isolates were inhibited by rRTI-1 sera, but none of them was inhibited by RTI-2 or control sera. Therefore, all of these HIV isolates were determined to be HIV-1. The isolates from three HIV-2-seropositive individuals were inhibited by RTI-2 but not RTI-1 (Table 4) . Additionally, rRTI-1 inhibited the enzyme activities of three AZT-resistant HIV-1 mutants, but RTI-2 did not. The proportions of residual RT activity with rRTI-1 were 1% for RT from A012D, 2% for RT from A018C, and 0% for RT from HTLV-IIIB R. In contrast, the proportions with RTI-2 were 126, 101, and 171%, respectively. 
DISCUSSION
Previous reports have described the specificity of RTI antibody for HIV-1 and HIV-2. It was reported that antibody from an HIV-1-infected individual and a rabbit immunized with disrupted HIV-1 specifically blocked HIV-1 RT but not other mammalian and avian retroviral RTs or DNA polymerase I (19) . Also, HIV-1 and HIV-2 antibodies from infected individuals were RT type specific; that is, they blocked HTLV-IIIB and simian immunodeficiency virus RTs, respectively (36) . However, it has not been extensively investigated whether RTI-1 and RTI-2 are type specific for other HIV-1 and HIV-2 strains or whether RTI antibodies produced against different strains all have similar type specificities.
For the RT-typing assay described here, we used rRTI-1 and RTI-2, which did not cross-react to HIV-2 and HIV-1 RTs by Western blot analysis. We did the RTI antibody assay with sera from HIV-1-infected Japanese individuals, some of which were cross-reactive to the HIV-2 RT protein by Western blot analysis. Using these RTIs, we showed in our study that the RTI-1 antibodies produced against different virus strains were specific for two HIV-1 strains and 18 clinical isolates from HIV-1-infected individuals, but not for HIV-2. We were unable to obtain serum from an HIV-2-infected individual, and therefore could only evaluate the specificity of a rabbit HIV-2 RTI antibody. In the RTI antibody assay, our result is in agreement with the results presented in a previous report (36) , in which 10 human HIV-2 RTI antiserum samples were specific for simian immunodeficiency virus but not for HTLV-"'B* Most likely, RTI-2 is specific only for most HIV-2 strains. (32) , or (ii) direct assays, which examine the virus by electron microscopy (8), Western blot pattern with known anti-HIV-1 or anti-HIV-2 sera, sequence analysis (25) , and more recently, PCR (14) . The relationship between the direct and the indirect methods is similar to that between the RT-typing assay with isolated HIV isolates and the RTI antibody assay with patient sera. Although the indirect methods are easy and rapid, they are not as specific because of their cross-reactivities. All of the direct methods for examining HIV are more laborious and costly than the RT-typing assay. PCR is excellent because of its exquisite sensitivity for direct HIV detection without virus isolation, but its specificity for HIV typing has not been well evaluated with isolates with drug resistance mutations (2, 26) .
The significance of determining the HIV type, and even the AZT resistance mutation, without the use of radioisotopes will depend on how rapid HIV-2 spreads and the development of selective HIV RT inhibitors for the treatment of the disease.
